Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6661042 | 0.80 | MEN1 (0.42) | TSHRMEN1LMNAHPGDBLM | |
| SCHEMBL11051153 | 0.78 | POLB (0.39) | TSHRPPARDGAA | |
| SCHEMBL11340245 | 0.78 | GAA (0.44) | TSHRLMNATDP1GAA | |
| SCHEMBL15475608 | 0.77 | KDM4E (0.35) | — | |
| SCHEMBL282439 | 0.76 | TSHR (0.52) | TSHRMEN1LMNAHPGDBLM | |
| SCHEMBL5697053 | 0.76 | LMNA (0.42) | TSHRMEN1LMNAHPGDBLM | |
| SCHEMBL2298239 | 0.74 | TSHR (0.50) | TSHRMEN1LMNAHPGDBLM | |
| SCHEMBL28021215 | 0.74 | TSHR (0.50) | TSHRMEN1LMNAHPGDBLM | |
| Hydrochloric Acid SCHEMBL15439306 | 0.74 | TSHR (0.50) | TSHRMEN1LMNAHPGDBLM | |
| SCHEMBL27617158 | 0.74 | L3MBTL1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118903088-A | Composition of fused tricyclic gamma-amino acid derivative and preparation thereof | 四川海思科制药有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-112384494-B | Composition of fused tricyclic gamma-amino acid derivative and preparation thereof | 四川海思科制药有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-111918859-B | Crystal forms of salts of fused tricyclic gamma-amino acid derivatives, preparation and use | 四川海思科制药有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-115677664-A | Pyridazinones as PARP7 inhibitors | 武汉人福创新药物研发中心有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-114423734-A | Metadiamide insecticides | FMC公司 | 2022-04-29 | — | — | CN | disclosed |
| US-7368476-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| WO-2005097770-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050227976-A1 | Novel hydroxamates as therapeutic agents | AXYS PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227976-A1 | Novel hydroxamates as therapeutic agents | HDAC1, HDAC5, HDAC10 | TSHR 3505/4885MEN1 4197/4885LMNA 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.